Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Company Overview

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing. As a clinical-stage company, its products remain investigational and have not been established as safe or effective for commercial use.

Key Stats

• Today's Range: $1.04 to $1.10
• 50-Day Range: $1.06 to $2.10
• 52-Week Range: $0.93 to $43.65
• Volume: 34,865 shs
• Average Volume: 822,134 shs
• Market Capitalization: $14.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Tvardi Therapeutics Stock Analysis - MarketRank™

Tvardi Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 476th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tvardi Therapeutics has a consensus price target of $18.00, representing about 1,622.5% upside from its current price of $1.05.

Amount of Analyst Coverage

Tvardi Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.35) to ($2.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tvardi Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tvardi Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tvardi Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.07% of the float of Tvardi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tvardi Therapeutics has a short interest ratio ("days to cover") of 2.29, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tvardi Therapeutics has recently decreased by 3.57%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tvardi Therapeutics does not currently pay a dividend.

Dividend Growth

Tvardi Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tvardi Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.40% of the stock of Tvardi Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TVRD
• Previous Symbol: NASDAQ:TVRD
• CIK: 1346830
• Web: www.tvarditherapeutics.com
• Phone: (713) 489-8654
• Fax: 203-567-1510
• Employees: 80
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Tvardi Therapeutics: $18.00
• High Price Target: $61.00
• Low Price Target: $5.00
• Potential Upside/Downside: +1,609.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.40%
• Return on Assets: -91.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 1.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.23 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 13,340,000
• Free Float: 12,352,000
• Market Cap: $14.05 million
• Optionable: N/A
• Beta: 0.38